Monday, February 27, 2012

Sensible Supervision Better than Blind Restriction on Paraquat

Paraquat is a very common herbicide in the world, but its fatal poisoning trait always arouses great concerns in the whole pesticide industry. Especially triggered by the suggestion from chemical experts of UN that paraquat dichlorid should become subject to the Prior Informed Consent (PIC) Procedure of The Rotterdam Convention, which was mentioned in March 2011, an explosive rumor about probable restriction on paraquat by the Chinese government spreads like wildfire, and shakes every paraquat player in China, according to CCM International’s February Issue of Herbicides China News.

Because of the frequent occurrence of paraquat poisoning deaths in China these years, the Chinese government expresses concern currently. And related governmental departments are working hard to enhance the supervision on paraquat management. Some officials from the Ministry of Agriculture (MOA) also pointed out that the government might take further restrictions on some pesticides in the near future, including paraquat, but no active policies has come out up to now in China.

In terms of paraquat pursuers in China, they have a great concern for the government's action towards paraquat because their future strategies about paraquat will be impacted by relative policies to some degree. In public, also, paraquat management in China has been disputed frequently. One opinion is to develop a new herbicide substitute for paraquat, and paraquat should be forbidden in the meantime in the wake of its sharp poisoning trait.

Regarding the dispute about whether paraquat should be forbidden or not in China, CCM International has discussed with Syngenta by E-mail, the largest paraquat player in the world at present. In the interview, Syngenta  expressed its exclusive viewpoints.
(J = Journalist of Herbicides China News, S = Syngenta)
J: Regarding recent rumor that China might take action to restrict paraquat, what is your opinion?
S: Syngenta welcomes the key elements of the proposal by MOA / ICAMA which focus on the stewardship. And Syngenta has an active dialogue with other producers in an effort to improve stewardship through the Paraquat Product Stewardship WorkGroup. We firmly believe that stewardship is a key to the safe use of the product. Thus we have invested in the safe use of paraquat in China through stewardship for many years, farmer support programs, and high quality formulations and packaging.

However, the restriction on paraquat in China should be considered carefully. The regrettable social phenomenon of suicide in rural communities of China has much more complex causes than the availability of farm chemicals. Removing one means of suicide from many others will not have any effect on the root causes of self-harm and is unlikely to make any impact on overall suicide levels. In fact, Syngenta's recent data show that paraquat is used in less than 1% of all pesticide-related suicides in China.

J: What's your suggestion about the stewardship of paraquat suicide in China?
S: The approach of a stewardship plan to manage the issue of suicide through ingestion of agricultural chemicals must involve multi stakeholders (e.g.: health, education, media and agriculture) and be on multi levels (regional, national and global). A comprehensive plan would include the management of access to the product, limitation of media publicity accompanied with the excessive reading of the product and the medical treatment improvement of poisoning.

China should strengthen the supervision of pesticide products as much as possible. For example, the package of liquid paraquat formulation nowadays should be improved—it should be packed in plastic bottle with thin bottleneck so that the liquid outflow time can be prolonged. Besides, liquid paraquat formulation can be changed to non-liquid paraquat formulation in public's advice, such as solid paraquat or powder-like paraquat.

Development of alternative formulations of paraquat will not be an easy or straightforward task as any alternative formulation would have to meet first and foremost the criteria of safety in normal use, as well as practical application and farmer affordability, whilst ensuring that the product continues to represent a viable business for manufacturers, its distributors and end-users.

Postscript from CCM International:
Statistics from CCM International show that there are more than 200 pesticide producers with paraquat production certificates in China. If paraquat was restricted in China, these enterprises will encounter great challenges and difficulties. The economic benefits that paraquat has brought to these enterprises and Chinese agriculture will vanish. Since paraquat is widely used in China, it is difficult to find a proper alternative and effective product to replace paraquat in a short time.

As a widely-used and eco-friendly herbicide with high efficiency, paraquat is still irreplaceable at present. As a non-selective herbicide with so many years' promotion, paraquat has witnessed fast development in the past decades in China, and has been playing an increasingly important role in weed control of orchards, corn fields, no-tillage fields and mulberry fields. China is the largest manufacturer of paraquat technical and formulations in the world.

According to the market report of Production and Market of Paraquat in China published by CCM International, as of May 2011, the paraquat technical capacity in China has reached 150,000t/a (calculated by 42% technical), maintaining the oversupply situation while the output of paraquat technical reached 120,000 tonnes in 2010 with the operating rate of 80%.

In accordance with CCM International's survey, the output of China's paraquat formulations has also grown very fast from more than 40,000 tonnes in 2006 to nearly 80,000 tonnes in 2010, with the average annual growth rate of 20%, which is mainly attributed to the rapid growth of domestic and overseas demand for paraquat during this period.

Thank Syngenta for contribution in this article and some contents were edited by Syngenta
(Similar report is mentioned in Herbicides China News 1109: Worries about paraquat aroused in China and Herbicides China News 0911: Controversy on paraquat poisoning: restricted or banned?)

Source: Herbicides China News 1202
http://www.cnchemicals.com/Newsletter/NewsletterDetail_11.html

Content of Herbicides China News 1202:
Sensible supervision better than blind restriction on paraquat
Huapont plans to invest in Brazilian market
Jiangsu Kuaida upgrades by relocation
Jiangsu Huifeng to meet expiration of diflufenican registration
Kunshan Raiser relocates into Binhai Industry Park
Glyphosate regulation in environmental protection enhanced
New tries in other industries become a trend
EU withdraws approval in acetochlor registration
Four export-oriented herbicides registered initially in H2 2011
Shandong Tianyuansen explores pyridine production
Sanonda to launch 2,4-D business
Jiangsu Changqing meets intense fomesafen supply
Shandong Yuhuang slacks its 75,000t/a EA project
Price Review in Feb. 2012
Glyphosate price remains stable in Feb.

Herbicides China News, a monthly publication issued by CCM International on 15th of every month, provides you with the latest occurrences, exclusive analysis on the market trend as well as professional reviews on competitiveness of companies, products and relative industries in China’s herbicide industry.


About CCM
CCM is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer.
For more information, please visit http://www.cnchemicals.com.
CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China
Tel: 86-20-37616606

Industrial Concentration of Chinese Glyphosate Increases in 2011

The long-term undervalued price and negative profit of glyphosate have led to the decrease in China's glyphosate technical capacity and lower operating rate of the less competitive manufacturers. The increasing proportion of glyphosate A.I. exports in the top glyphosate manufacturers has revealed the increase in industrial concentration of Chinese glyphosate industry in 2011, which will result in a better glyphosate market in 2012, according to CCM International’s February Issue of Glyphsoate China Monthly Report.

Although it's hard to get every glyphosate manufacturer's actual output, the export volume from companies exporting glyphosate is a good reference for estimating the industrial concentration of Chinese glyphosate industry, as more than 83% of China's glyphosate products have been exported in the past ten years. In 2011, China has exported about 300,000 tonnes of glyphosate technical, which is estimated to account for 85% of China's total output.
 
In 2010, the total export volume of glyphosate A.I. manufactured by the top six companies accounted for 55.5%-61.3% of China's total exports (interval value is given because manufacturers of some records can't be identified).
 
But in 2011, the total export volume of glyphosate A.I. manufactured by the top six companies has taken up 66.5%-69.6% of China's total glyphosate A.I. exports.
 
In terms of export volume, the share of the top 10 glyphosate manufacturers accounted for 69.5%-76.8% in 2010, whilst the top 10 took up 82.4%-86.2% in 2011.
 
According to CCM International's analysis, glyphosate products exported in 2010 are manufactured by 54 manufacturers, and glyphosate products exported in 2011 are manufactured by 45 manufacturers.

The increase in industrial concentration has reflected the integration process of Chinese glyphosate industry, and there will be smaller and smaller space for the less competitive glyphosate manufacturers. It's predicted that industrial concentration will continue to increase in 2012, and there will be a more rational market.

Source: Glyphsoate China Monthly Report 1202
http://www.cnchemicals.com/Newsletter/NewsletterDetail_14.html

Content of Glyphsoate China Monthly Report 1202:
Zhejiang Wynca involved in trouble of "chemical salt sold to edible salt market" case
Brazil keeps high growth in adoption of GM crops in 2011
Australia lodges anti-dumping petition on formulated glyphosate from China
Industrial concentration of Chinese glyphosate increases in 2011
Chinese glyphosate faces four challenges in 2012
A new method to treat glyphosate mother liquid and recycle its nitrogen and phosphorous elements
Glycine market keeps gloomy
Glyphosate price in February 2012
Glyphosate export significantly grows in December 2011
Overview of glyphosate export in 2011

Glyphosate China Monthly Report, a monthly publication issued by CCM International on 20th of every month, will keep track of latest dynamics, hotspots and competitiveness analysis, and forecasts on market trends of China’s glyphosate industry.

About CCM
CCM is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer.
For more information, please visit http://www.cnchemicals.com.
CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China
Tel: 86-20-37616606

China Restricts Inorganic Fluoride Development by Rising Entry Criteria

China's government raised the entry criteria to guide the development of inorganic fluoride industry, according to CCM’s January Issue of China Fluoride Materials Monthly Report.

On February 14th, 2011, the Ministry of Industry and Information Technology of the P.R.C. (MIIT) promulgated the Entry Criteria for Hydrogen Fluoride (HF) Industry (the Entry Criteria) which aims to restrict the blind expansion of HF.

The Entry Criteria sets up regulations in industry distribution, scale, technology& equipment, energy saving and comprehensive utilization of resources, environmental protection, product quality, etc.

According to the Entry Criteria, in principle, it is not allowed to set up new plant or expand the existing scale, except the development and production of specialty high grade products for high purity and ultra-clean electronics industry and the raw material for the utilization of enterprises themselves. Regarding to the new plants, the production capacity shall not be less than 50,000t/a and the single set device capacity shall not be less than 20,000t/a.

Besides, the new plants must have matching devices for waste treatment.

Regarding to energy saving and comprehensive utilization of resources, it requests that in producing one tonne of HF, fluorite (CaF2>97%) shall be no more than 2.25 tonnes; integrated water consumption shall not exceed one tonne; the average annual overall energy consumption of coal shall not be more than 450 kg. Meanwhile, HF production enterprises shall develop circular economy, improving the comprehensive utilization of energy, echelon fluorite and fluorine gypsum slag. The content of calcium sulfate in gypsum slag containing fluoride shall not be less than 90%, with the calcium fluoride content of no more than 2%, and the sulfuric acid content shall not exceed 0.5%, with the comprehensive utilization rate of over 90% (including commission processing and utilization of long-term contracts). The existing manufacturers which can not meet these requirements must be shut down.

Moreover, the Entry Criteria also regulates that fluorite enterprises can not sell fluorite to the HF producers which can not meet the Entry Criteria. Meanwhile, the HF producers can not purchase fluorite from the fluorite enterprises which can not meet the Entry Criteria for Fluorite which came into effective in Mar. 2010.

Apart from the Entry Criteria, the Guided Catalogue for Industrial Structure Adjustment (2011)(Guidance Catalog), which was promulgated by the National Development and Reform Commission (NDRC) in March 2011, also restricts the development of inorganic fluoride chemicals, including HF and AlF3.

According to the Guidance Catalog, new HF plant and AlF3 production lines with single line production capacity of lower than 20,000t/a are restricted. And HF and AlF3 with the production capacity of lower than 5,000t/a shall be shut down.

China is the biggest producer of HF in the world. There are about 50 HF manufacturers in China. Among these producers, 40 have the production capacity of over 10,000t/a, and 10 have capacity of over 30,000t/a. The total domestic capacity of hydrogen fluoride is about 1,253,000t/a in 2010.

Source: China Fluoride Materials Monthly Report 1201

Main content of China Fluoride Materials Monthly Report 1201:
Fluorite resource attracts more investment
China continues to revoke export quota system for fluorite ore in 2012
Phosphorus-fluorine integrated industry to benefit fluorine industry
China to completely eliminate HCFCs by 2030
Shanghai 3F benefits from capacity expansion and price raising
China's global market share for AlF3 shrinks in 2010-2011
China restricts inorganic fluoride development by rising entry criteria
India extends anti-dumping duty on China's PTFE for five years
China's fluoropolymer industry attracts more foreign investment
Zhejiang Juhua to extend fluoride product portfolio
Fluoride fine chemical production booming in Fuxin, Liaoning
LiPF6 production to boom in China
China still a net exporter of fluoride chemicals
Prices of fluoride materials drop in November

China Fluoride Materials Monthly Report, a monthly publication issued by CCM International on 20th of every month, covers the sectors on policy & legislation, company dynamic, supply & demand, price update, etc. of China’s fluoride material market. It will help you follow the dynamic throughout the whole value chain immediately.


About CCM International
CCM International is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM International offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer. For more information, please visit http://www.cnchemicals.com.

CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China
Tel: 86-20-37616606

Thursday, February 23, 2012

Ukraine Has Officially Run Anti-dumping Investigation into China's Citric Acid

On 31 Jan. 2012, the Ministry of Commerce of China published an announcement, according to which, Ukraine's government made a decision on 23 Jan. 2012 that the country would run an anti-dumping investigation into China's citric acid, and it has been officially executed since 27 Jan. 2012. The result of this investigation may come out by Jan. 2013. More importantly, it's worried that Ukraine's anti-dumping investigation may arouse unwanted chain reaction that more and more countries will follow suit, according to CCM International’s February issue of Corn Products China News.

Actually, this is not the first time that Ukraine has run anti-dumping investigations into China's citric acid. In May 2003, Ukraine began to run an anti-dumping investigation into the product, and the final decision published in Mar. 2004 stated that Ukraine would levy anti-dumping duty (it was the price spread between CIF price and the bottom price of USD977/t ruled by Ukraine) on China's citric acid in the next five years. For example, if the CIF price of China's citric acid to Ukraine was USD800/t, the duty would be USD177/t. And the very reason behind the anti-dumping investigation in 2003 was that the selling price of China's citric acid in Ukraine was 42.3% lower than that of home-made one in the East European country from 2000 to 2002, resulting in the 13.6% market share decline of Ukraine's producers.
 
Ukraine's reason for the investigation in 2012 is that it believes from Q4 2010 to Q3 2011, citric acid from China was imported at dumping prices, which could do harm to Ukraine's producers. In fact, according to China Customs, the average export price of China's citric acid was only USD786/t in 2010, much lower than the bottom price of USD977/t. Although from Mar. to June 2011, the monthly average export prices all stayed at over USD1,000/t, other monthly prices were still lower than the bottom price.

In the short run, it's believed that Ukraine's new anti-dumping investigation won't bring much negative effect on China's citric acid industry. Up till now, no Chinese producer has definitely revealed appeals yet, because Ukraine is not a key export destination of China's citric acid in recent years. For instance, the export volume of citric acid to Ukraine during the whole year of 2011 was only about 5,082 tonnes, just accounting for 0.73% of the product's total export volume that year.
 
But in the long term, it's worried that the Ukraine's investigation may arouse chain reaction that more and more countries will follow suit. For example, on 16 Jan. 2012, the Ministry of Commerce of China published an article, revealing that Thailand is likely to continue levying anti-dumping duty on China's citric acid with the rate of 38.1% in the next five years. Thailand began to run an anti-dumping investigation into China's citric acid in 2003, and the final decision made in 2004 ruled that Thailand would levy a 38.1% anti-dumping duty on China's citric acid in the next five years. And in Jan. 2011, Thailand decided to continue levying 38.1% anti-dumping duty on the product in question from Jan. 2011 to Jan. 2012 in its sunset review.
 
In 2011, India, Japan, Turkey, Indonesia and Russia were the top 5 export destinations of China's citric acid, whose aggregate import volume of the product reached 177,465 tonnes, accounting for about 25.6% of China's total export volume in the year. At present, these countries haven't taken any anti-dumping or anti-subsidy measures on China's citric acid, but some insiders are still worried that they will follow to run related investigations in the future.

Source: Corn Product China News 1202

Content of Corn Products China News 1202:
Chinese DDGS import volume declines by 46.7% in 2011
Export volume of VB2 witnesses a decline in 2011
Chinese corn products Imp. & Exp. analysis in December 2011
Domestic price of furfural rebounds in 2012
Corn starch price in China enjoys slight uptrend in Feb. 2012
Ukraine has officially run anti-dumping investigation into China's citric acid
Baolingbao to market IMO end product in H1 2012
Xiwang Sugar witnesses poor performance in Q4 2011
China Starch's expansion plan to be postponed
Northeast Pharmaceutical to lose USD54.0-69.8 million in 2011
Domestic home-made potato starch price heads down in Feb. 2012
11.5%, corn's import volume increases in 2011

Corn Products China News, a monthly publication issued by CCM International on 20th of every month, reveals the driving force of news stories and deeply analyzes the influence of trends and dynamics on domestic and international corn deep processing industry.


About CCM International
CCM International is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM International offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer. For more information, please visit http://www.cnchemicals.com.

CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China
Tel: 86-20-37616606

MOH Announces Progress on Public Hospitals Expenditures Control


For healthcare spending, according to TABLE 1, total health expenditure as a proportion of GDP for 2010 from World Health Databook of Euromonitor, China ranks significantly lower than other countries do; the 5.2% of GDP spending is much lower than that of other major pharmaceutical markets such as the US, Japan, Germany and France. It is also lower than other BRIC countries (except for India). The financial funding from Chinese government is insufficient to support the healthcare services that are carried out primarily by public hospitals.

Public hospitals provide over 90% of medical services. Over 40-50% income of hospitals is from drugs. The hospital expenditure control is fundamentally the control of drug consumption, especially the expensive drugs. This is not a new idea; Shanghai Health Bureau had implemented the mandate hospital expenditure control in 1996, a policy penalized hospitals with drug income growth exceeding 15% over the previous year. An obvious effect on control of the soaring growth is observed. The overall hospital income growth of Shanghai in 1994 was over 50% before it decreased to 20% in 1996, while the percentage of drug income in Shanghai hospitals' total income had dropped from over 60% in 1994 to less than 50% in 1996.

It is not surprising a similar result with the Ministry of Health control on hospital expenditure will be expected from the past experience of the Shanghai Health Bureau. What important is the reality that drug income is still critical for hospitals. The government is still struggling with the conflict of controlling the hospital expenditures without financial compensation to hospitals. Chinese hospitals are under government's control but operating based on market, so they have to obtain profit to survive. Controlling their income will have a negative impact on the hospitals' operation. In the long run, the success of these governmental policies will be limited without considering the market driven hospital system.

Another interesting observation is the figures of hospital expenditure growth reported by MOH seem to be very low. Based on the fact that drug income contributes to about 40-50% of hospitals’ income, the 5% growth of the income is contradictory to the drug market growth rate of over 25%. It may be due to the increased drug sales from selfpay market and lower tier health centers. This is in line with some big pharmaceutical players' strategies; a good example is the proactive over 50% price cut of Zocor, a cholesterol lowering drug under EDL from Merck aiming at the penetration to lower tier market.

Source: Pharmaceuticals China Bimonthly Report 1201

Main content of Pharmaceuticals China Bimonthly Report 1201:
-MOH announces progress on public hospitals expenditures control NDRC updates essential drugs tendering system & healthcare reform
-SFDA ensures essential drugs safety and supply
-SFDA strengthens control on internet drug selling
-Major therapeutic classes market review-- Cancer market review
-Antibiotic control impact
-SFDA requested recall of Caelyx and Velcade
-Chinese pharmaceuticals received FDA approval
-HBV therapeutic vaccine Phase III trial continues
… …

Pharmaceuticals China Bimonthly Report, published on 20th bimonthly, can keep you informed of the changes and implications of regulations and policies in China’s pharmaceutical market. By grasping the latest market and product development trends on specific therapeutic classes for decision making, you might understand the potential long-term change of market trend based on potential technologies and drugs under development.


About CCM International
CCM International is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM International offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer. For more information, please visit http://www.cnchemicals.com.

CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China
Tel: 86-20-37616606

Major Therapeutic Classes Market Review -- Cancer Market Review

According to International Agency for Research on Cancer under WHO (2008 data), China is the second highest cancer-incidence country in the world with over 2.2 million new cancer cases every year. The figures are even higher from Chinese Cancer Registry Annual Report 2009 (3.6 million). The ten leading cancers and their prevalence in China are listed in TABLE 2. Cancer drugs contribute to 10% of the total prescription drug market in China, and grow at an annual rate of 25% which is higher than the overall pharmaceutical market growth of 18%. The total cancer market is about USD4 billion. Cancer market is attracting pharmaceutical companies and we are seeing a clear trend for them to make more efforts to capture the potential, according to CCM’s January Issue of Pharmaceuticals China Bimonthly Report.

Cancer drugs are classified generally based on their mechanism of action.
-- Alkylating agents
-- Platinum compounds
-- Antimetabolites
-- Natural plant derivatives
-- Antineoplastic antibiotics
-- Antineoplastic monoclonal antibodies and target therapeutics
-- Cytostatic hormones
-- Adjuvant drugs
-- Traditional Chinese medicines

Natural plant derivative drugs have the biggest market share while monoclonal-and-targettherapeutics drugs and hormonal drugs have the highest growth rates.

Local generic drugs are dominating the market with over 70% of the market share by value.

Source: Pharmaceuticals China Bimonthly Report 1201

Main content of Pharmaceuticals China Bimonthly Report 1201:
-MOH announces progress on public hospitals expenditures control NDRC updates essential drugs tendering system & healthcare reform
-SFDA ensures essential drugs safety and supply
-SFDA strengthens control on internet drug selling
-Major therapeutic classes market review-- Cancer market review
-Antibiotic control impact
-SFDA requested recall of Caelyx and Velcade
-Chinese pharmaceuticals received FDA approval
-HBV therapeutic vaccine Phase III trial continues
-BMS and Simcere expand strategic cooperation
-Simcere launches Iremod for active rheumatoid arthritis
-AstraZeneca expands local manufacturing
-Boehringer Ingelheim expands Shanghai factory
-MSD sets up Asia R&D center in Beijing
-Global CRO targets China market
… …

Pharmaceuticals China Bimonthly Report, published on 20th bimonthly, can keep you informed of the changes and implications of regulations and policies in China’s pharmaceutical market. By grasping the latest market and product development trends on specific therapeutic classes for decision making, you might understand the potential long-term change of market trend based on potential technologies and drugs under development.



About CCM International
CCM International is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM International offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer. For more information, please visit http://www.cnchemicals.com.

CCM International Ltd.
Guangzhou CCM Information Science & Technology Co., Ltd.
17th Floor, Huihua Commercial & Trade Mansion, No.80 Xianlie Zhong Road, Guangzhou 510070, China
Tel: 86-20-37616606